The new HemoPoint® H2 now recalls 4,000 patient results, an improvement from the previous 100 test result memory, ensuring accurate patient data tracking. A hemoglobin and calculated hematocrit result can now be read in as little as 10 seconds. The time to result is measurably faster than the previous model, allowing for accurate testing in a time critical setting. The improved HemoPoint® H2 also has a new battery backlight feature, improving readability throughout the self prompting test procedure, including the final result screen.
These improved features along with the new HemoPoint® H2 nxt microcuvette, make Stanbio Laboratory's HemoPoint® H2 hemoglobin and hematocrit test system a true upgrade from the original H2.
The HemoPoint® H2 provides both a hemoglobin and hematocrit result, using a single drop of whole blood, with one simple test. Hemoglobin testing is routinely performed in blood banks, public health clinics, operating theaters, intensive care units and trauma centers. Point-of-care hemoglobin testing is also run by OB/GYNs, as well as, general and pediatric physicians.
Founded in 1960 and headquartered in Boerne, Texas, Stanbio manufactures and sells medical testing and diagnostic devices including clinical chemistry, pregnancy, drugs of abuse, serology, urinalysis, and point-of-care blood hemoglobin tests. Stanbio Laboratory's Quality System is ISO 13485 registered and its facility operates under the USFDA current GMP requirements. Stanbio also offers OEM and private labeling capabilities. Currently, Stanbio distributes products in over 110 countries worldwide. This year the company celebrates its 49th year in business. To find out more about Stanbio, review its news, or learn more about its products, visit www.stanbio.com.
(# # #)